NUTSHELL

NUTSHELL has long been dedicated to the research and development of allosteric drugs and is currently the world's leading and China's only platform-based allosteric new drug R&D company. The company’s team consists of top scientists in the global allosteric field, as well as senior experts from well-known multinational pharmaceutical companies (MNCs) and the Artificial Intelligence Drug Discovery (AIDD) domain. NUTSHELL owns the world’s earliest, largest, and most comprehensive allosteric database. Leveraging its self-developed AI + allosteric drug discovery platform, the company focuses on developing lead molecules via allosteric mechanisms for undruggable targets (from 0 to 1) and accelerating drug development (from 1 to 10). Based on this platform, NUTSHELL has developed multiple pipelines, including First-in-Class pipelines targeting novel targets. Compared with traditional methods, NUTSHELL’s platform significantly reduces the time and cost of allosteric drug R&D and can be commercialized through self-development, co-development, or License-out models.